arrow
R

Ryan Larson

umoja biopharma
H指数:19
被引数:2,400

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

In vivo engineering of T cells with a synthetic cytokine receptor enables selective enrichment and expansion of anti-CD22 CAR T cells

体内工程化T细胞,通过合成细胞因子受体实现抗CD22 CAR T细胞的特异性富集和扩增

2026-08-100
PRE
A Synthetic Receptor Enables Breakthrough Scale Manufacturing of iPSC-Derived CD19-CAR Cell Therapies for Hematologic and Autoimmune Diseases

一种合成受体实现了iPSC来源的CD19-CAR细胞疗法在血液疾病和自身免疫疾病治疗中的突破性规模制造。

BLOOD
IF23.1
2024-11-050
PRE
Vivovec™ Surface-Engineered Lentiviral Particles Mediate In Vivo CAR T Generation with Potent and Highly Durable Activity in Non-Human Primates

Vivovec™表面工程化慢病毒颗粒介导体内CAR T生成,并在非人灵长类动物中展现出强效且高度持久的活性。

BLOOD
IF23.1
2024-11-050
PRE
MiR-155-regulated molecular network orchestrates cell fate in the innate and adaptive immune response to Mycobacterium tuberculosis

MiR-155-regulated分子网络在对结核分枝杆菌的先天性和适应性免疫反应中协调细胞命运

2016-09-28106
OAAI